4001 results about "Endocrinology" patented technology

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time-correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

Systems and methods for monitoring glucose variability in a subject are described. Data indicative of glucose levels of the subject is received from a sensor control device. A first glucose variability metric of the subject in a first time period is determined. The first glucose variability metric may be compared to a threshold. A first indicator is displayed if the first glucose variability metric does not exceed the threshold and a second indicator is displayed if the first glucose variability metric exceeds the threshold. Additional glucose variability metrics may be determined for subsequent time periods according to a rolling window, and the indicators may be displayed real time or in a report. The glucose variability metric may be a measure of variability compared to a baseline, a difference between a maximum and minimum glucose level, or time in or out of a target range.

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The disclosure provides methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines. The present disclosure also provides methods to reduce the SSRI washout period in patients prior to administration of psilocybin therapy.

The present disclosure provides methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

The invention belongs to the field of food, and particularly relates to a nutritional composition containing probiotics and breast milk oligosaccharide for improving anxiety or depression and application of the nutritional composition. The invention provides application of a nutritional composition in preparation of food beneficial to improving constipation and anxiety state and / or depression state caused by constipation. Wherein the nutritional composition comprises the following components (i) and (ii): (i) a bifidobacterium probiotic, and (ii) a sialylated breast milk oligosaccharide; the bifidobacterium probiotics at least comprise animal bifidobacterium subsp. Lactis, the sialylated breast milk oligosaccharide at least comprises 6 '-sialylated lactose, and the animal bifidobacterium subsp. Lactis comprises a Bb-12 strain. The substance combination of the bifidobacterium probiotics and the sialylated breast milk oligosaccharide can synergistically improve abnormal brain-intestine interaction, and improve constipation and anxiety and / or depression state caused by constipation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and / or reducing relapse of agitation in Alzheimer's disease.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The invention relates to an application of metformin in preparation of skin anti-photoaging drugs or medical instruments. Through verification, the metformin has the effects of promoting the formation of autophagosome, recovering the patency of autophagy flow and remodeling an autophagy-ECM metabolism regulation network. After the composition is applied to the skin (such as a corium layer), the effect of resisting skin photoaging is achieved by adjusting an AMPK signal channel. The metformin is used as an active ingredient to prepare a medicine or a medical instrument, and is beneficial to clinically anti-photoaging application of the skin.

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

The present disclosure provides methods of treating a SYNGAP1-related disorder in a subject by administering a therapeutically effective amount of N-acetyl leucine.

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The invention provides a compound of formula (I), or salt thereof,wherein:A, B, C, D, W, X, Y and Z are each independently selected from H and OH; for use in a method of enhancing or improving fertility in a male or female subject, for example, a human male subject. The invention also provides a method of enhancing or improving fertility in a subject (for example a male subject) comprising administering a compound of formula (I) to the subject, and compositions that find use in such methods.

The invention relates to the technical field of blood glucose prediction, in particular to a blood glucose fluctuation prediction method based on historical data. The method comprises the following steps: acquiring corresponding historical blood glucose monitoring data, daily behavior data, physiological status data and medical intervention data of a user, performing time axis alignment and abnormal value cleaning treatment, and extracting basic features and associated influence features corresponding to blood glucose fluctuation; performing space-time dimension fusion on the basic features and the associated influence features, and generating a blood glucose fluctuation prediction curve of the user in a future preset time period; performing comparative analysis on the blood glucose fluctuation prediction curve and actual blood glucose monitoring data of the user, calculating a prediction deviation degree and a trend goodness of fit, and generating a corresponding deviation analysis result; feature weight distribution of the dynamic prediction model is optimized based on the deviation analysis result, and a personalized blood glucose fluctuation prediction report is generated and comprises a risk early warning threshold value and an intervention suggestion triggering condition. According to the method, prediction efficiency and personalized management of blood glucose fluctuation can be realized.

The invention discloses a system and a method for intelligently monitoring blood sugar of a patient before and after diet based on food components, and belongs to the technical field of blood sugar monitoring, and the system comprises a food component quantification module which is used for converting a food image or description into accurate macro nutrient and micronutrient data; the multi-modal data fusion module is used for preprocessing and fusing the multi-modal data of the patient; the patient blood sugar prediction module is used for constructing a patient blood sugar prediction model to analyze the multi-modal fusion data of the patient and predicting the blood sugar of the patient; and the difference analysis optimization module is used for comparing actual blood glucose with predicted blood glucose after meal and analyzing difference reasons. The problems that blood glucose of a patient before and after eating cannot be intelligently monitored, and accurate quantification and prediction of the relation between diet and blood glucose cannot be achieved are solved. The system can intelligently monitor the blood glucose of the patient before and after eating, can help the diabetic to realize accurate quantification and prediction of the relationship between diet and blood glucose, and can effectively control the blood glucose and reduce the risk of complications.

The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Provided herein is, among other things, is a method of treating cancer using an improved intermittent dosing regimen for Azenosertib, or a pharmaceutically acceptable salt thereof, administration to achieve a highly efficacious, safe and tolerable dosing regimen to treat many different types of cancers. In one aspect, the method of treating cancer comprises administering a daily dose of Azenosertib, or a pharmaceutically acceptable salt thereof, (e.g., greater than about 350 mg) in accordance with an improved intermittent dosing cycle, wherein the intermittent dosing cycle comprises one or more dosing weeks with each dosing week comprising between about 2-7 consecutive dosing days and between about 1-7 days without dosing. In some embodiments, the intermittent dosing cycle is repeated wherein the dosing weeks are separated by a break of one, two or more weeks. In some aspects, Azenosertib, or a pharmaceutically acceptable salt thereof, is administered as a combination therapy.

The invention belongs to the technical field of biological medicine, and particularly discloses application of kaempferol in preparation of a medicine for treating chronic obstructive pulmonary disease. The invention provides application of kaempferol in preparation of a medicine for treating chronic obstructive pulmonary disease. The invention provides a medicine for treating chronic obstructive pulmonary disease. The medicine comprises kaempferol or pharmaceutically acceptable salt thereof as an active ingredient. The invention aims to provide the application of kaempferol in preparation of the medicine for treating the chronic obstructive pulmonary disease, and the chronic obstructive pulmonary disease is treated by adjusting an AMPK signal channel, a Hippo signal channel, an MAPK signal channel and a PI3K-AKT signal channel.